Relay Therapeutics (RLAY) Stock Price, Quote, News & History | Benzinga

Relay Therapeutics Inc (RLAY) Stock Price, Quote, News & History

RLAYNASDAQ

Trade with Public

Trade with Public

$19.44

-0.26-1.32%

At close: Aug 20, 5:00 PM EST

$19.25

-0.45-2.3%

Pre-Market: 8:22 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$19.44

Volume / Avg.

4.54K / 3.50M

Day Range

- - -

52 Wk Range

3.31 - 21.27

Market Cap

$4.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

21.39%

Days to Cover

17.41

Recent Relay Therapeutics, Inc. News

Advance Auto Parts Posts Upbeat Q1 Earnings, Joins IBM, Ralph Lauren And Other Big Stocks Moving Higher On Thursday

U.S. stocks were lower on Thursday, with Nasdaq falling over 200 points. Advance Auto Parts Inc (NYSE: AAP) jumped 16.4% after reporting better-than-expected Q1 results.

Avi Kapoor

Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in pre-market trading. Photo via Shutterstock

Avi Kapoor

Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with zovegalisib.

Vandana Singh

Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets raised for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO.

Avi Kapoor

Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?

Relay Therapeutics shares rise after Phase 3 data show zovegalisib achieved 11.1-month PFS in metastatic breast cancer patients.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-212.21M

Investing Cash Flow (TTM)

-244.94M

Financing Cash Flow (TTM)

463.47M

Free Cash Flow (TTM)

-212.21M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

6.33M

Analyst Trends and Forecast

5

Apr

4

May

3

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.38B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

342.15

PB Ratio (TTM)

4.79

Earnings Yield % (TTM)

-8.02%

Earnings Yield % (FWD)

-8.08%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.06

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$121.19M

Debt to Equity

0.03

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$19.44

Volume / Avg.

4.54K / 3.50M

Day Range

- - -

52 Wk Range

3.31 - 21.27

Market Cap

$4.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

21.39%

Days to Cover

17.41

About

Sector

Health Care

Industry

Biotechnology

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and e...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Relay Therapeutics (RLAY) stock?

A

You can purchase shares of Relay Therapeutics (NASDAQ:RLAY) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Relay Therapeutics (RLAY) competitors?

A

Other companies in Relay Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Relay Therapeutics (RLAY) stock?

A

Relay Therapeutics has a consensus price target of $21.95.

Q

What is the current price for Relay Therapeutics (RLAY)?

A

The stock price for Relay Therapeutics (NASDAQ: RLAY) is $19.247 last updated August 24, 2026 at 8:23 AM EDT.

Q

Does Relay Therapeutics (RLAY) pay a dividend?

A

There are no upcoming dividends for Relay Therapeutics.

Q

When is Relay Therapeutics (NASDAQ:RLAY) reporting earnings?

A

Relay Therapeutics does not have any upcoming earnings scheduled.

Q

Is Relay Therapeutics (RLAY) going to split?

A

There is no upcoming split for Relay Therapeutics.

Q

What sector and industry does Relay Therapeutics (RLAY) operate in?

A

Relay Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.